(94) showed that CDKN2A deletions or loss of heterozygosity, which are commonly found in non-Caucasian patients with melanoma, were significantly enriched in patients with progressing melanomas after treatment with ICIs (nivolumab, pembrolizumab, or nivolumab plus ipilimumab). This evidence concerns the gene CDKN2A and melanoma.